2Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involve- ment and treatment response in immunoglobulin light chain amy- loidosis (AL):a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis [ J 1. Am J Hematol,2005, 79(4) :319 -328.
3Guidelines Working Group of UK Myeloma Forum, British Commit- tee for Standards in Haematology. Guidelines on the diagnosis and management of AL amyloidosis [ J ]. Br J Haemato1,2004,125 ( 6 ) : 681 - 700.
1Kindy MS, De Beer FC. Amyloidosis. In:Massry SG, Glassock RJ, eds. Textbook of nephrology. 4th ed. Philadephia: Lippincott Williams and wilkins,2001.824-829.
2Amyloidosis. In: Kern WF, Silva FG, Laszik ZG, et al, eds. Atlas of renal pathology. Philadephia: W.B.Saunders Company,1999.221-228.
3Falk RH, Comenzo RL, Skinner M. He systemic amyloidoses.N Engl J Med,1997, 337:898-909.
8Skinner M.Treatment of 100 patients with primary amyloidosis: a randomized trial of melphlan, prednisone, and colchicines only[].The American Journal of Medicine.1996
9Gertz MG.Primary systemic amyloidosis: a diagnostic primery[].Mayo Clinic Proceedings.1989
